Piramal completes Grangemouth ADC expansion
Piramal Healthcare says expanded antibody drug conjugate (ADC) capacity will support 2011 launch of new cancer drug by US biotech partner.
The expansion, at Piramal’s plant in Grangemouth, Scotland, added extra manufacturing and quality control (QC) laboratory space.
Piramal also unveiled plans to add commercial scale manufacturing suites which, spokeswoman Nicole Tingley, described as a significant step forward for an increasingly important part of the firm’s manufacturing business.
“By adding production capacity of launched products to our proven development and clinical trial phase expertise the new investment offers long-term benefits to customers developing ADC products.”
